Mitsubishi Tanabe Pharma Corporation has announced that the FDA accepted the company’s New Drug Application for edaravone (MCI-186) which is an intravenous treatment for ALS. Based on the Prescription Drug User Fee Act, a decision is expected to be made …
Cytokinetics Completes Enrollment in VITALITY-ALS
Thank you to all the ALS patients who have volunteered to participate in the Cytokinetics Phase III clinical trial of tirasemtiv in ALS at the Lois Insolia ALS Clinic at the Les Turner ALS Research and Patient Center at Northwestern …
ALS Walk for Life Sponsor Announces New Collaboration
The Les Turner ALS Foundation is happy to share great news about one of our ALS Walk for Life event sponsors, Cytokinetics. The drug development company has finalized a deal to collaborate with global pharma company, Astellas to conduct further research …
National ALS Registry Updates
As proud partners of the National ALS Registry, Les Turner ALS Foundation Executive Director, Andrea Pauls Backman and Director of Patient Services, Judy Richman, attended the Annual Agency for Toxic Substances and Disease Registry (ATSDR) Meeting in Atlanta this week. …
Every August Until A Cure
In August 2014, a viral phenomenon took over social media feeds across the globe with people accepting the ALS Ice Bucket Challenge. Friends challenging friends, patients challenging celebrities and teenagers challenging grandparents to douse themselves with ice cold water while …
Guidelines for Clinical Trials in ALS/MND – 2016 update
This past March, 140 international thought leaders in the field of ALS met at the ALS Clinical Trials Guidelines 2016 Workshop. Among those in attendance included Dr. Teepu Siddique and Dr. Senda Ajroud-Driss on behalf of the Les Turner Research …
